Amador ML - Search Results

1

Synthesis and antitumor evaluation of benzoylphenylurea analogs.

Gurulingappa H, Amador ML, Zhao M, Rudek MA, Hidalgo M, Khan SR. Gurulingappa H, et al. Among authors: amador ml. Bioorg Med Chem Lett. 2004 May 3;14(9):2213-6. doi: 10.1016/j.bmcl.2004.02.019. Bioorg Med Chem Lett. 2004. PMID: 15081011

2

Design, synthesis and biological evaluation of novel riccardiphenol analogs.

Kumar SK, Amador M, Hidalgo M, Bhat SV, Khan SR. Kumar SK, et al. Bioorg Med Chem. 2005 Apr 15;13(8):2873-80. doi: 10.1016/j.bmc.2005.02.010. Bioorg Med Chem. 2005. PMID: 15781397

3

Epidermal growth factor receptor as a therapeutic target for the treatment of colorectal cancer.

Amador ML, Hidalgo M. Amador ML, et al. Clin Colorectal Cancer. 2004 May;4(1):51-62. doi: 10.3816/ccc.2004.n.010. Clin Colorectal Cancer. 2004. PMID: 15207021 Review.

4

Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer.

Jimeno A, Rubio-Viqueira B, Amador ML, Grunwald V, Maitra A, Iacobuzio-Donahue C, Hidalgo M. Jimeno A, et al. Among authors: amador ml. Mol Cancer Ther. 2007 Mar;6(3):1079-88. doi: 10.1158/1535-7163.MCT-06-0448. Mol Cancer Ther. 2007. PMID: 17363501

5

An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.

Amador ML, Oppenheimer D, Perea S, Maitra A, Cusatis G, Iacobuzio-Donahue C, Baker SD, Ashfaq R, Takimoto C, Forastiere A, Hidalgo M. Amador ML, et al. Cancer Res. 2004 Dec 15;64(24):9139-43. doi: 10.1158/0008-5472.CAN-04-1036. Cancer Res. 2004. PMID: 15604284

6

Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents.

Jimeno A, Rubio-Viqueira B, Amador ML, Oppenheimer D, Bouraoud N, Kulesza P, Sebastiani V, Maitra A, Hidalgo M. Jimeno A, et al. Among authors: amador ml. Cancer Res. 2005 Apr 15;65(8):3003-10. doi: 10.1158/0008-5472.CAN-04-3586. Cancer Res. 2005. PMID: 15833824

7

Progress in the development and acquisition of anticancer agents from marine sources.

Amador ML, Jimeno J, Paz-Ares L, Cortes-Funes H, Hidalgo M. Amador ML, et al. Ann Oncol. 2003 Nov;14(11):1607-15. doi: 10.1093/annonc/mdg443. Ann Oncol. 2003. PMID: 14581267 Free article. Review. No abstract available.

8

Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration.

Hidalgo M, Amador ML, Jimeno A, Mezzadra H, Patel P, Chan A, Nielsen ME, Maitra A, Altiok S. Hidalgo M, et al. Among authors: amador ml. Mol Cancer Ther. 2006 Jul;5(7):1895-903. doi: 10.1158/1535-7163.MCT-05-0525. Mol Cancer Ther. 2006. PMID: 16891476

9

Assessment of celecoxib pharmacodynamics in pancreatic cancer.

Jimeno A, Amador ML, Kulesza P, Wang X, Rubio-Viqueira B, Zhang X, Chan A, Wheelhouse J, Kuramochi H, Tanaka K, Danenberg K, Messersmith WA, Almuete V, Hruban RH, Maitra A, Yeo CJ, Hidalgo M. Jimeno A, et al. Among authors: amador ml. Mol Cancer Ther. 2006 Dec;5(12):3240-7. doi: 10.1158/1535-7163.MCT-06-0565. Mol Cancer Ther. 2006. PMID: 17172427 Clinical Trial.

10

An in vivo platform for translational drug development in pancreatic cancer.

Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, Shi C, Danenberg K, Danenberg PV, Kuramochi H, Tanaka K, Singh S, Salimi-Moosavi H, Bouraoud N, Amador ML, Altiok S, Kulesza P, Yeo C, Messersmith W, Eshleman J, Hruban RH, Maitra A, Hidalgo M. Rubio-Viqueira B, et al. Among authors: amador ml. Clin Cancer Res. 2006 Aug 1;12(15):4652-61. doi: 10.1158/1078-0432.CCR-06-0113. Clin Cancer Res. 2006. PMID: 16899615

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

24 results

Search Page